The startup develops personalized cell therapies for vascular diseases using a combination of vascular endothelial progenitor cells and mesenchymal stem cells to regenerate blood vessels. This approach provides symptomatic relief for patients requiring interventions such as vascular bypass surgery, stents, and balloon angioplasty.
Funding
Funding not disclosed
Founders
Product
Problem
Patients with severe vascular diseases often require invasive procedures like bypass surgery, stents, and angioplasty to restore blood flow, but these interventions provide only symptomatic relief and do not address the underlying tissue damage. Current treatments often fail to achieve complete vascular regeneration, leading to recurring ischemia and the need for repeated interventions.
Solution
Elpis Cell Therapeutics develops personalized cell therapies to regenerate blood vessels and provide long-term relief for patients with vascular diseases. The company's lead candidate, EL-100, is a composite stem cell therapy derived from the patient's own bone marrow, consisting of vasculogenic mesenchymal stem cells (vMSC) and mesenchymal stem cells (MSC). These cells work synergistically to promote angiogenesis and repair damaged vascular tissue. Elpis Cell Therapeutics is also developing EL-200, an anti-cancer immunotherapy using Memory Like NK Cells, and EL-300, a stem cell mobilizing agent for treating bone marrow suppression.
Target Audience
The primary target audience includes patients with severe peripheral artery disease, critical limb ischemia, and other vascular conditions who are seeking regenerative therapies to improve blood flow and avoid amputation, as well as patients with cancer and those undergoing chemotherapy.
Features
- EL-100: Autologous bone marrow-derived composite stem cell therapy for severe vascular diseases
- EL-100: Consists of vasculogenic mesenchymal stem cells (vMSC) and mesenchymal stem cells (MSC)
- EL-200: Memory Like NK Cell (ML-NK Cell) anti-cancer immunotherapy
- EL-300: Substance P stem cell mobilizing agent for treating bone marrow suppression
- Proprietary methods for isolating and expanding vMSCs with enhanced angiogenic potential
- GMP-compliant cell manufacturing process
- Pipeline includes treatments for Buerger’s disease, diabetic foot ulcers, and stroke